AlphaGazette
Menu

Medicine and health

Science

FDA rejects Summit's ivonescimab, finding no significant survival benefit

Summit Therapeutics said Sunday it received a complete response letter on the lung cancer drug it is developing with Akeso. Its Nasdaq shares fell around 13 percent Monday morning.

  • The FDA refused Summit’s application for ivonescimab in EGFR-mutated non-small cell lung cancer.
  • Regulators said overall survival in the Phase III HARMONi trial was not statistically significant, a bar they had set for approval.
  • Median time before the cancer worsened was 6.8 months on ivonescimab versus 4.4 months on placebo.

1 min read 4 sources